Diagnostic Challenges during Inflammation and Cancer : Current Biomarkers and Future Perspectives in Navigating through the Minefield of Reactive versus Dysplastic and Cancerous Lesions in the Digestive System
In the setting of pronounced inflammation, changes in the epithelium may overlap with neoplasia, often rendering it impossible to establish a diagnosis with certainty in daily clinical practice. Here, we discuss the underlying molecular mechanisms driving tissue response during persistent inflammatory signaling along with the potential association with cancer in the gastrointestinal tract, pancreas, extrahepatic bile ducts, and liver. We highlight the histopathological challenges encountered in the diagnosis of chronic inflammation in routine practice and pinpoint tissue-based biomarkers that could complement morphology to differentiate reactive from dysplastic or cancerous lesions. We refer to the advantages and limitations of existing biomarkers employing immunohistochemistry and point to promising new markers, including the generation of novel antibodies targeting mutant proteins, miRNAs, and array assays. Advancements in experimental models, including mouse and 3D models, have improved our understanding of tissue response. The integration of digital pathology along with artificial intelligence may also complement routine visual inspections. Navigating through tissue responses in various chronic inflammatory contexts will help us develop novel and reliable biomarkers that will improve diagnostic decisions and ultimately patient treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 25(2024), 2 vom: 19. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pateras, Ioannis S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Artificial intelligence |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 29.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms25021251 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367696681 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367696681 | ||
| 003 | DE-627 | ||
| 005 | 20240129232226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240127s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms25021251 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1274.xml |
| 035 | |a (DE-627)NLM367696681 | ||
| 035 | |a (NLM)38279253 | ||
| 035 | |a (PII)1251 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pateras, Ioannis S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnostic Challenges during Inflammation and Cancer |b Current Biomarkers and Future Perspectives in Navigating through the Minefield of Reactive versus Dysplastic and Cancerous Lesions in the Digestive System |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 29.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In the setting of pronounced inflammation, changes in the epithelium may overlap with neoplasia, often rendering it impossible to establish a diagnosis with certainty in daily clinical practice. Here, we discuss the underlying molecular mechanisms driving tissue response during persistent inflammatory signaling along with the potential association with cancer in the gastrointestinal tract, pancreas, extrahepatic bile ducts, and liver. We highlight the histopathological challenges encountered in the diagnosis of chronic inflammation in routine practice and pinpoint tissue-based biomarkers that could complement morphology to differentiate reactive from dysplastic or cancerous lesions. We refer to the advantages and limitations of existing biomarkers employing immunohistochemistry and point to promising new markers, including the generation of novel antibodies targeting mutant proteins, miRNAs, and array assays. Advancements in experimental models, including mouse and 3D models, have improved our understanding of tissue response. The integration of digital pathology along with artificial intelligence may also complement routine visual inspections. Navigating through tissue responses in various chronic inflammatory contexts will help us develop novel and reliable biomarkers that will improve diagnostic decisions and ultimately patient treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a artificial intelligence | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a digital pathology | |
| 650 | 4 | |a dysplasia | |
| 650 | 4 | |a immunohistochemistry | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a molecular biology | |
| 650 | 4 | |a pathology | |
| 650 | 4 | |a reactive atypia | |
| 650 | 4 | |a tissue response | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Igea, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Nikas, Ilias P |e verfasserin |4 aut | |
| 700 | 1 | |a Leventakou, Danai |e verfasserin |4 aut | |
| 700 | 1 | |a Koufopoulos, Nektarios I |e verfasserin |4 aut | |
| 700 | 1 | |a Ieronimaki, Argyro Ioanna |e verfasserin |4 aut | |
| 700 | 1 | |a Bergonzini, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Ryu, Han Suk |e verfasserin |4 aut | |
| 700 | 1 | |a Chatzigeorgiou, Antonios |e verfasserin |4 aut | |
| 700 | 1 | |a Frisan, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Kittas, Christos |e verfasserin |4 aut | |
| 700 | 1 | |a Panayiotides, Ioannis G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 25(2024), 2 vom: 19. Jan. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:2 |g day:19 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms25021251 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 2 |b 19 |c 01 | ||